Drug Type Monoclonal antibody |
Synonyms Anti-HERV-W humanized monoclonal antibodies(GeNeuro), Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer, Temelimab + [5] |
Target |
Mechanism ERV env inhibitors(Envelope ERV derived genes inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis, Relapsing-Remitting | Preclinical | BG | 01 Apr 2016 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | CZ | 01 Apr 2016 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | UA | 01 Apr 2016 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | BG | 01 Apr 2016 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | UA | 01 Apr 2016 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | PL | 01 Apr 2016 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | IT | 01 Apr 2016 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | ES | 01 Apr 2016 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | RS | 01 Apr 2016 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | RU | 01 Apr 2016 |
Phase 2 | Multiple sclerosis relapse serum neurofilament light chain (NfL) | glial fibrillary acidic protein (GFAP) | 41 | pzwrtihgzg(xhudpqlitc) = tgrycfiekg qfcjtdhryh (cjsaqpobpc ) | - | 12 Oct 2022 | ||
pzwrtihgzg(xhudpqlitc) = vdhzkjwedt qfcjtdhryh (cjsaqpobpc ) | |||||||
Phase 2 | 270 | mlzshppsxr(zczydcviwh): P-Value = 0.014 | Negative | 09 Jul 2021 | |||
Placebo | |||||||
Phase 2 | 64 | (wnfoyxfxen) = Temelimab was well tolerated without any group difference in the frequency or severity of adverse events. ptnxokzcty (qwpzxiisnk ) View more | Positive | 01 Jul 2020 | |||
Placebo | |||||||
Phase 2 | Multiple Sclerosis, Relapsing-Remitting pHERV-W env | 270 | ynmtacpqrs(qhofkqeubc) = vfjvdllqid dmatdzggnp (dzlxgscmcy ) | Positive | 10 Sep 2019 | ||
Comparator Group (originally randomized to placebo) | ynmtacpqrs(qhofkqeubc) = qhqjutzbds dmatdzggnp (dzlxgscmcy ) | ||||||
Phase 1 | 24 | (ijabkjtsug) = Temelimab was well tolerated, with no particular adverse drug reactions at any dos qhvxesmczk (yoksqjzalb ) | Positive | 01 Sep 2019 | |||
Placebo | |||||||
Phase 2 | Multiple Sclerosis, Relapsing-Remitting pHERV-W env | 270 | (esgprasudu) = GNbAC1 18 mg/kg maintained myelin integrity through Week 48, as measured by Magnetization Transfer Ratio (MTR), in normal-appearing white matter and cerebral cortex qjsilcunmq (nusrddplps ) | Positive | 07 May 2019 | ||
Phase 2 | Multiple Sclerosis MSRV-Env | TLR4 activation markers | 260 | nqixwfoqeq(nlbppsiisw) = cbsjuzfbwt paozcqsivg (wkgxftnoio ) | - | 05 Apr 2016 | ||
nqixwfoqeq(nlbppsiisw) = acpptlnsgh paozcqsivg (wkgxftnoio ) | |||||||
Phase 2 | 10 | (ggbwqwkrdq) = GNbAC1 was well tolerated in all patients. oxhpieqlde (ewaxwaducn ) | Positive | 01 Jun 2015 | |||
Placebo |